A public consultation on guidance on the use of disease modifying drugs (DMDs) for people in England with relapsing MS is open until 5 May 2018
Results from a large clinical trial of siponimod for secondary progressive MS (SPMS) have been published. Those taking siponimod had a 21% reduced risk of progression.
Preliminary data from an international stem cell study for people with relapsing multiple sclerosis has reported that those having stem cell treatment had fewer relapses and improved disability levels.
The manufacturers of Zinbryta (daclizumab) announce worldwide withdrawal of Zinbryta following new reports of serious side effects
The Scottish Medicines Consortium (SMC) has approved Mavenclad (cladribine) as a treatment for highly active relapsing multiple sclerosis.
The government has announced a review of all 1.6 million personal independence payment (PIP) claims following a High Court ruling.
The MS Trust is dismayed by NICE's recommendation. We do not believe it is in the best interests of people with MS or the NHS.